Herndon Christopher M, Nguyen Van
School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL, 62026, USA.
Hospital Sisters Health System, O'Fallon, IL, 62269, USA.
J Pain Res. 2022 Sep 29;15:3069-3077. doi: 10.2147/JPR.S373295. eCollection 2022.
Viral arthropathy is an increasingly recognized sequela of several viral pathogens including alphaviruses, hepatitis, and potentially coronaviruses. Case reports of viral arthropathy and myalgia associated with SARS-CoV-2 infection (COVID-19) both during active disease and following resolution of acute COVID-19 symptoms are becoming more prevalent. We sought to describe the prevalence of viral arthropathy and myalgia associated with COVID-19, as well as to identify factors that may predict these symptoms.
A national, cross-sectional survey was conducted using a questionnaire administered online. Subjects self-reporting previous confirmed COVID-19 were recruited using the Amazon Mechanical Turk crowdsourcing platform. Questionnaire items included demographics, frequency and severity of common COVID-19 symptoms, requirement for hospitalization or mechanical ventilation, subject recall of arthropathy or myalgia onset, duration, and severity, as well as WOMAC score. Binary logistic regression was used to identify potential predictive co-variates for the development of either arthropathy or myalgia.
A total of 3222 participants completed the arthropathy/myalgia questionnaire with 1065 responses remaining for analysis following application of exclusion criteria, data integrity review, and omission of respondents with confounding conditions. Of the 1065 cases, 282 (26.5%) reported arthralgia and 566 (53.2%) reported myalgia at some point during or after COVID-19 with 9.9% and 6.0% reporting onset of arthralgia or myalgia, respectively, after resolution of acute COVID-19 symptoms. The presence of several commonly reported COVID symptoms or indicators of disease severity was predictive of arthralgia including hospitalization (OR 3.7; 95% CI 2.4 to 5.8), sore throat (OR 2.3; 95% CI 1.5 to 3.5), fatigue (OR 2.9; 95% CI 1.7 to 4.9), and ageusia/anosmia (OR 1.7; 95% CI 1.1 to 2.7).
Based on these results, new-onset arthropathy and myalgia following COVID-19 resolution may be an increasingly encountered etiology for pain.
病毒性关节病是包括甲病毒、肝炎病毒以及可能的冠状病毒在内的多种病毒病原体感染后越来越被认识到的一种后遗症。与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染(新冠肺炎)相关的病毒性关节病和肌痛在疾病活动期以及急性新冠肺炎症状消退后的病例报告越来越普遍。我们试图描述与新冠肺炎相关的病毒性关节病和肌痛的患病率,并确定可能预测这些症状的因素。
使用在线问卷进行了一项全国性横断面调查。通过亚马逊土耳其机器人众包平台招募自我报告曾确诊感染新冠肺炎的受试者。问卷项目包括人口统计学信息、常见新冠肺炎症状的频率和严重程度、住院或机械通气需求、受试者对关节病或肌痛发作、持续时间和严重程度的回忆,以及西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分。采用二元逻辑回归确定关节病或肌痛发生的潜在预测协变量。
共有3222名参与者完成了关节病/肌痛问卷,在应用排除标准、数据完整性审查并排除有混杂情况的受访者后,剩余1065份回复可供分析。在这1065例病例中,282例(26.5%)报告在新冠肺炎期间或之后的某个时间出现关节痛,566例(53.2%)报告出现肌痛,分别有9.9%和6.0%的患者在急性新冠肺炎症状消退后出现关节痛或肌痛。几种常见报告的新冠肺炎症状或疾病严重程度指标的存在可预测关节痛,包括住院(比值比[OR]3.7;95%置信区间[CI]2.4至5.8)、咽痛(OR 2.3;95%CI 1.5至3.5)、疲劳(OR 2.9;95%CI 1.7至4.9)以及嗅觉减退/嗅觉丧失(OR 1.7;95%CI 1.1至2.7)。
基于这些结果,新冠肺炎症状消退后新发的关节病和肌痛可能是越来越常见的疼痛病因。